Clene Inc
CLNN - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$56.15M
Close$
$-1.81
145.8% downside
Current Fair Value
145.8% downsideOvervalued by 145.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $56.15 Million |
|---|---|
| Enterprise Value | $68.86 Million |
| Earnings per Share | $-2.65 |
| Beta | 0.92 |
| Outstanding Shares | 13,079,599 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | -121.07% |
| Return on Invested Capital | -223.06% |
Valuation & Multiples
| P/E Ratio | -1.65 |
|---|---|
| PEG | 1.14 |
| Price to Sales | - |
| Price to Book Ratio | -1.98 |
| Enterprise Value to Revenue | 289.34 |
| Enterprise Value to EBIT | -6.12 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.33 |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
November 4, 2026
EPS Estimate
$-0.45
Consensus analyst estimateRevenue Estimate
$70,000
Consensus analyst estimateNext Earnings Call
Expected Date
March 11, 2027
EPS Estimate
$-0.49
Consensus analyst estimateRevenue Estimate
$67,500
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.56%▼ 25.13% |
|---|---|
| Total Invested | $283,683▼ 98.55% |
| Investors Holding | 3▼ 30.00% |
About Clene Inc
2,021 employees
Clene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally a...